AMT: A New Substance for the Treatment of Advanced Cancer

The SanaFontis Cancer Hospital at Freiburg currently investigates AMT, a new

substance for the treatment of advanced cancer. The hospital has its own study centre
in which it develops and improves a number of new tumour therapies. The hospital’s
aim is to offer cancer patients promising treatment options as quickly as possible,
explains the clinic’s medical director, Dr Joachim Drevs. In that respect, AMT
represents an exciting new approach to tumour treatment. The substance is a mixture of
herbal and synthetic components, the anti-neoplastic effect of all of which has been
scientifically confirmed long ago. Among other substances, AMT contains camomile,
insulin, and antihistamines – all substances with a known anti-neoplastic activity. In
AMT, they have been combined in a new formulation.

AMT has only minor side effects

Results from the AMT pilot phase preceding the current study showed that the majority
of tumour patients responded to the treatment. In some cases, even tumour regression
was achieved. In fact, AMT seems to have a modulating effect on the immune system.
At the same time, AMT dosing was observed to improve patients’ quality of life: they
gained weight, and tumour pain lessened, while side effects were very few and minor.
This low rate of side effects has already been observed in previous studies. The
objective of the AMT studies conducted at the SanaFontis Hospital is to confirm under
controlled [study] conditions any results so far available and, as a consequence, enable
cancer patients to benefit from AMT as soon as possible. Therefore, the drug is being
used to treat various solid tumours and examined for efficacy. AMT seems to be
particularly effective against hepatic, pancreatic, intestinal and cervical cancer.

1
AMT Studies at a Glance

Solid tumours
Phase II/III study with AMT to determine the drug’s safety, tolerability and its effect on the
quality of life in patients with various advanced-stage solid tumours.

Hepatocellular cancer
Phase II study with AMT to determine the drug’s safety and its effect on tumour growth in
patients with advanced-stage primary liver cancer (hepatocellular carcinoma).

Pancreatic cancer
Phase II study with AMT to determine the drug’s safety and progression-free (no tumour
growth) survival in patients with advanced-stage pancreatic cancer.

Colorectal cancer
Phase II study to evaluate the safety and progression-free (no tumour growth) survival in
patients with advanced-stage colorectal cancer.

The SanaFontis Cancer Hospital

SanaFontis is a new cancer hospital with 85 beds. It focuses on individualised and holistic
medical care for cancer patients with solid tumours, lymphomas and certain leukemia. The
hospital’s philosophy is to combine state-of-the-art diagnostic and therapeutic procedure
with affectionate and committed medical care for the patients. The hospital is a committed
to standard therapy, but always keeps an open mind for new therapeutic approaches and
complementary methods of treatment.

For further information please contact:

Cancer Hospital SanaFontis
An den Heilquellen 2
79111 Freiburg

Medical information Centre

Phone: +49 (0761) 888 59 5874
Fax : +49 (0761) 888 59 5957
E-mail: medinfo@sanafontis.com
www.sanafontis.com